Recently, Huaxi Bio and Haohaishengke completed their registration in science and technology innovation board, and their profitability and ultra-high gross profit margin attracted people's attention. According to the prospectus, in 20 18, the net profit of Huaxi Bio reached 424 million yuan, and that of Haohai Ke Sheng reached 455 million yuan. From 20 16 to 20 18, the gross profit margin of the main business of these two companies remained above 75%.
In 20 18, the gross profit margin of Haohaishengke hyaluronic acid products reached 93.26%. Hyaluronic acid itself is a kind of hyaluronic acid existing in human dermis, which is responsible for storing water and making skin look full. Injection of hyaluronic acid is used to remove wrinkles and solve problems such as facial depression, but it can only last for about 6-8 months. According to the research report of CITIC Securities, it is estimated that by 2020, China hyaluronic acid cosmetic needle will become a market of 654.38 billion yuan.
Then, is hyaluronic acid with high gross profit margin, high repurchase rate and huge market space a good business? Many people in the industry told Combustion Finance that the upstream manufacturers of hyaluronic acid can basically obtain stable and high profits because there are few products approved by the State Administration of Medical Supplies in the market at present, which basically forms a monopoly, and micro-plastic surgery is a popular entry-level standard project for medical beauty, with low threshold, good effect, low risk and huge market space, and qualified manufacturers can indeed make profits.